IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Sauter, M. et al U.S. Appln. No. : To Be Accorded Confirmation No. : To Be Accorded U.S. Filing Date : 10/20/2003 Title of Invention : Improved Process For P Attny. Docket No.: 1/1208-4-D3) Art Unit:) Examiner: Preparing Zolpidem	1625 P. L. Morris
Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450		
October 20, 2003		
TRANSMITTAL LETTER FOR INFO	ORMATION DISCL	OSURE STATEMENT
Sir:		
Transmitted herewith concerning the subject Statement (Form 1449A/B) under 37 C.F.R. hereinbelow.	t application is an Inf §§1.56 and 1.97, as r	ormation Disclosure more specifically described
In accordance with the duty of disclosure un the U.S. Patent and Trademark Office of the PTO-1449 form and which the Examiner mathe above-identified application. Copies of filed in US Application No. 10/446,434, file Docket No. 1/1208-3-D2).	documents listed her ay deem relevant to pa the citations listed on	rein and on the attached atentability of the claims of the PTO-1449 form are
1.97(b). This Statement is being date of a national application other than a constant \$1.53 (d); ii) within three (3) months of the 37 C.F.R. §1.491 in an international application on the merits; or iv) before the mailing of a continued examination under 37 C.F.R. §1.1	ontinued prosecution and date of entry of the nation; iii) before the material first Office action after the material action	ational stage as set forth in alling of a first Office action
1.97(c). This Statement is bein C.F.R. §1.97(b), but before the mailing date notice of allowance under 37 C.F.R. §1.311 prosecution in the application. This Statement	of: i) a final action u, or iii) an action that	otherwise closes

		A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
□ §1.97(statem §1.17(ent as s	This Statement is being filed after the period specified in 37 C.F.R. n or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	· 1.97(e)).
	counte	Each item of information contained in the instant information disclosure ent was first cited in any communication from a foreign patent office in a repart foreign application not more than three (3) months prior to the filing of tant information disclosure statement; or
	foreign makin inform C.F.R.	No item of information contained in the instant information disclosure ent was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after greasonable inquiry, no item of information contained in the instant action disclosure statement was known to any individual designated in 37 \$1.56(c) more than three (3) months prior to the filing of the instant action disclosure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclo	1.704(sure sta erpart aj	(d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a opplication, which communication was not received by any individual designated

in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Alan R. Stempel

Attorney for Applicant(s)

Reg. No. 28,991

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-4868 Date: October 20, 2003

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

a collection of information unless it contains a valid OMB control number. Inder the Paperwork Reduction Act of 1995, no persons are required to respond to Complete if Known Substitute for form 1449A/PTO Application Number To Be Accorded Filing Date 10/20/2003 INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

First Named Inventor Markus SAUTER Art Unit 1625 **Examiner Name** Patricia L. MORRIS

(Use as many sheets as necessary) Attorney Docket Number 1/1208-4-D3

	0.4	D	U. S. PATENT D Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Examiner nitials*	Cite No.1	Document Number	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant
nitiais"	NO.		MIMI-DD-1111	Applicant of Cited Document	Figures Appear
		Number-Kind Code ^{2 (I known)}			riguies Appeai
		US-			
		US-			
		US-			
		US-			<u>.</u>
		US-			
		US-	***************************************		
	 	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ 'Number ⁴ 'Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		EP 0 251 859 B1	11/22/1990	Synthelabo		
						
	İ					
	1		<u> </u>			
						

Examiner	 Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known Application Number To Be Accorded INFORMATION DISCLOSURE Filing Date 10/20/2003 First Named Inventor STATEMENT BY APPLICANT Markus SAUTER Art Unit 1625 (Use as many sheets as necessary) Examiner Name Patricia L. MORRIS Sheet Attorney Docket Number 2 1/1208-4-D3

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
		TRAPANI, ET AL; "Novel 2-Phenylimidazo[1,2-alpha]pyridine Derivatives as Potent and Selective Ligands for Peripheral Benzodiazepine Receptors: Synthesis, Binding Affinity, and in Vivo Studies"; J. Med. Chem. 1999, 42(19), pgs 3934-3941		
		TRAPANI, ET AL; "Synthesis and Binding Affinity of 2-Phenylimidazo[1,2-alpha]pyridine Derivatives for both Central and Peripheral Benzodiazepine Receptors. A New Series of High-Affinity and Selective Ligands for the Peripheral Type"; J. Med. Chem. 1997, 40(19), pgs 3109-3118		
1			•••••	
	!			
			•	
	•••••		•••••	
	•		•••••	
Examiner Signature	<u> </u>	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.